Striatal Transcriptome and Interactome Analysis of Shank3-overexpressing Mice Reveals the Connectivity between Shank3 and mTORC1 Signaling

Mania causes symptoms of hyperactivity, impulsivity, elevated mood, reduced anxiety and decreased need for sleep, which suggests that the dysfunction of the striatum, a critical component of the brain motor and reward system, can be causally associated with mania. However, detailed molecular pathophysiology underlying the striatal dysfunction in mania remains largely unknown. In this study, we aimed to identify the molecular pathways showing alterations in the striatum of SH3 and multiple ankyrin repeat domains 3 (Shank3)-overexpressing transgenic (TG) mice that display manic-like behaviors. The results of transcriptome analysis suggested that mammalian target of rapamycin complex 1 (mTORC1) signaling may be the primary molecular signature altered in the Shank3 TG striatum. Indeed, we found that striatal mTORC1 activity, as measured by mTOR S2448 phosphorylation, was significantly decreased in the Shank3 TG mice compared to wild-type (WT) mice. To elucidate the potential underlying mechanism, we re-analyzed previously reported protein interactomes, and detected a high connectivity between Shank3 and several upstream regulators of mTORC1, such as tuberous sclerosis 1 (TSC1), TSC2 and Ras homolog enriched in striatum (Rhes), via 94 common interactors that we denominated “Shank3-mTORC1 interactome”. We noticed that, among the 94 common interactors, 11 proteins were related to actin filaments, the level of which was increased in the dorsal striatum of Shank3 TG mice. Furthermore, we could co-immunoprecipitate Shank3, Rhes and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 (WAVE1) proteins from the striatal lysate of Shank3 TG mice. By comparing with the gene sets of psychiatric disorders, we also observed that the 94 proteins of Shank3-mTORC1 interactome were significantly associated with bipolar disorder (BD). Altogether, our results suggest a protein interaction-mediated connectivity between Shank3 and certain upstream regulators of mTORC1 that might contribute to the abnormal striatal mTORC1 activity and to the manic-like behaviors of Shank3 TG mice.

[1]  Bokyoung Lee,et al.  Age-dependent decrease of GAD65/67 mRNAs but normal densities of GABAergic interneurons in the brain regions of Shank3-overexpressing manic mouse model , 2017, Neuroscience Letters.

[2]  G. Feng,et al.  Striatopallidal dysfunction underlies repetitive behavior in Shank3-deficient model of autism , 2017, The Journal of clinical investigation.

[3]  Bokyoung Lee,et al.  Integrative Analysis of Brain Region-specific Shank3 Interactomes for Understanding the Heterogeneity of Neuronal Pathophysiology Related to SHANK3 Mutations , 2017, Front. Mol. Neurosci..

[4]  G. Feng,et al.  SHANK proteins: roles at the synapse and in autism spectrum disorder , 2017, Nature Reviews Neuroscience.

[5]  I. Filonova,et al.  Novel Shank3 mutant exhibits behaviors with face validity for autism and altered striatal and hippocampal function , 2017, Autism research : official journal of the International Society for Autism Research.

[6]  Núria Queralt-Rosinach,et al.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..

[7]  P. Calabresi,et al.  Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice , 2017, Molecular Psychiatry.

[8]  K. Khare,et al.  RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network (“Rhesactome”) in the striatum , 2016, Science Signaling.

[9]  Bokyoung Lee,et al.  Bipolar Disorder Associated microRNA, miR-1908-5p, Regulates the Expression of Genes Functioning in Neuronal Glutamatergic Synapses , 2016, Experimental neurobiology.

[10]  R. Weinberg,et al.  The Postsynaptic Density: There Is More than Meets the Eye , 2016, Front. Synaptic Neurosci..

[11]  M. Matamales,et al.  Quantitative Imaging of Cholinergic Interneurons Reveals a Distinctive Spatial Organization and a Functional Gradient across the Mouse Striatum , 2016, PloS one.

[12]  R. Weinberg,et al.  Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism , 2016, Nature Communications.

[13]  C. McClung,et al.  Animal models of bipolar mania: The past, present and future , 2016, Neuroscience.

[14]  Tadafumi Kato,et al.  Animal models of recurrent or bipolar depression , 2016, Neuroscience.

[15]  Jeffrey A. Porter,et al.  CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency , 2016, Science.

[16]  B. Sabatini,et al.  Early hyperactivity and precocious maturation of corticostriatal circuits in Shank3B−/− mice , 2016, Nature Neuroscience.

[17]  Zhandong Liu,et al.  Post-transcriptional regulation of SHANK3 expression by microRNAs related to multiple neuropsychiatric disorders , 2015, Molecular Brain.

[18]  Laura Inés Furlong,et al.  PsyGeNET: a knowledge platform on psychiatric disorders and their genes , 2015, Bioinform..

[19]  Núria Queralt-Rosinach,et al.  DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes , 2015, Database J. Biol. Databases Curation.

[20]  H. Zoghbi,et al.  Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice. , 2015, Human molecular genetics.

[21]  K. Doya,et al.  Distinct Neural Representation in the Dorsolateral, Dorsomedial, and Ventral Parts of the Striatum during Fixed- and Free-Choice Tasks , 2015, The Journal of Neuroscience.

[22]  J. Krystal,et al.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. , 2015, Annual review of medicine.

[23]  Thomas Frauenfelder,et al.  Quantitative imaging. , 2015, Investigative radiology.

[24]  A. Kolevzon,et al.  A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome , 2014, Molecular Autism.

[25]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[26]  Christopher S. Poultney,et al.  Synaptic, transcriptional, and chromatin genes disrupted in autism , 2014, Nature.

[27]  Elodie Ey,et al.  Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments , 2014, PLoS genetics.

[28]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[29]  P. Calabresi,et al.  Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.

[30]  H. Nawa,et al.  mTOR signaling and its roles in normal and abnormal brain development , 2014, Front. Mol. Neurosci..

[31]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[32]  T. Boeckers,et al.  The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation , 2014, Experimental Neurology.

[33]  Thomas Bourgeron,et al.  The emerging role of SHANK genes in neuropsychiatric disorders , 2014, Developmental neurobiology.

[34]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[35]  R. Dolmetsch,et al.  SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients , 2013, Nature.

[36]  N. Sonenberg,et al.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.

[37]  M. Costa-Mattioli,et al.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders , 2013, Nature Neuroscience.

[38]  A. Breman,et al.  SHANK3 overexpression causes manic-like behavior with unique pharmacogenetic properties , 2013, Nature.

[39]  Y. Ahn,et al.  Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates mTOR signal pathways and protein translation in the rat frontal cortex , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  J. Buxbaum,et al.  Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay , 2013, Molecular Autism.

[41]  M. Ehlers,et al.  Modeling Autism by SHANK Gene Mutations in Mice , 2013, Neuron.

[42]  Pasko Rakic,et al.  Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. , 2013, Genes & development.

[43]  R. Straub,et al.  Effect of Schizophrenia Risk-Associated Alleles in SREB2 (GPR85) on Functional MRI Phenotypes in Healthy Volunteers , 2013, Neuropsychopharmacology.

[44]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[45]  Christian Appenzeller‐Herzog,et al.  Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. , 2012, Trends in cell biology.

[46]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[47]  S. Snyder,et al.  Rhes, a striatal–enriched small G–protein, mediates mTOR signaling and L–DOPA–induced dyskinesia , 2011, Nature Neuroscience.

[48]  T. Boeckers,et al.  Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. , 2011, Trends in cell biology.

[49]  M. Austin,et al.  The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  M. Chiappalone,et al.  Importance of Shank3 Protein in Regulating Metabotropic Glutamate Receptor 5 (mGluR5) Expression and Signaling at Synapses , 2011, The Journal of Biological Chemistry.

[51]  Diana V. Dugas,et al.  Protein Interactome Reveals Converging Molecular Pathways Among Autism Disorders , 2011, Science Translational Medicine.

[52]  Simon Tavaré,et al.  Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes , 2011, Science.

[53]  H. Weiss,et al.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. , 2011, Cancer research.

[54]  R. Kessler,et al.  Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. , 2011, Archives of general psychiatry.

[55]  G. Feng,et al.  Shank3 mutant mice display autistic-like behaviours and striatal dysfunction , 2011, Nature.

[56]  Zbyszek Otwinowski,et al.  Structure and Control of the Actin Regulatory WAVE Complex , 2010, Nature.

[57]  S. Hyman,et al.  Animal models of neuropsychiatric disorders , 2010, Nature Neuroscience.

[58]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[59]  Y. Ahn,et al.  Activation of Akt signaling in rat brain by intracerebroventricular injection of ouabain: A rat model for mania , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[60]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[61]  Marie-Pierre Dubé,et al.  De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia , 2010, Proceedings of the National Academy of Sciences.

[62]  H. Manji,et al.  Translational research in bipolar disorder: emerging insights from genetically based models , 2010, Molecular Psychiatry.

[63]  E. Klann,et al.  mTOR signaling: At the crossroads of plasticity, memory and disease , 2010, Trends in Neurosciences.

[64]  Kuei Yuan Tseng,et al.  Handbook of basal ganglia structure and function , 2010 .

[65]  Steven E. Hyman,et al.  Animal models of neuropsychiatric , 2010 .

[66]  B. Balleine,et al.  Human and Rodent Homologies in Action Control: Corticostriatal Determinants of Goal-Directed and Habitual Action , 2010, Neuropsychopharmacology.

[67]  M. Sheng,et al.  Regulated RalBP1 Binding to RalA and PSD-95 Controls AMPA Receptor Endocytosis and LTD , 2009, PLoS biology.

[68]  N. Craddock,et al.  Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk , 2009, Molecular Psychiatry.

[69]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[70]  H. Lôo.  [On bipolar disorder]. , 2008, L'Encephale.

[71]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[72]  A. Meyer-Lindenberg,et al.  The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia , 2008, Proceedings of the National Academy of Sciences.

[73]  Emma L. Jenkins,et al.  Inhibition of Arp2/3-mediated actin polymerization by PICK1 regulates neuronal morphology and AMPA receptor endocytosis , 2008, Nature Cell Biology.

[74]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[75]  Christian R Marshall,et al.  Contribution of SHANK3 mutations to autism spectrum disorder. , 2007, American journal of human genetics.

[76]  S. Buono,et al.  Schizophrenia in a patient with subtelomeric duplication of chromosome 22q , 2007, Clinical genetics.

[77]  M. Leboyer,et al.  Fronto-striatal overactivation in euthymic bipolar patients during an emotional go/nogo task. , 2007, The American journal of psychiatry.

[78]  Thomas Bourgeron,et al.  Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders , 2007, Nature Genetics.

[79]  Shiro Suetsugu,et al.  The WASP–WAVE protein network: connecting the membrane to the cytoskeleton , 2007, Nature Reviews Molecular Cell Biology.

[80]  D. Pinto,et al.  Contribution of SHANK 3 Mutations to Autism Spectrum Disorder , 2007 .

[81]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Robert T. Abraham,et al.  Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.

[83]  S. Paradiso,et al.  Cognitive and neurological impairment in mood disorders. , 2004, The Psychiatric clinics of North America.

[84]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[85]  Hoi-Chung Leung,et al.  Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. , 2003, The American journal of psychiatry.

[86]  F. Benes,et al.  GABAergic Interneurons: Implications for Understanding Schizophrenia and Bipolar Disorder , 2001, Neuropsychopharmacology.

[87]  W. Berrettini,et al.  Are schizophrenic and bipolar disorders related? A review of family and molecular studies , 2000, Biological Psychiatry.

[88]  M. Sheng,et al.  The Shank family of scaffold proteins. , 2000, Journal of cell science.

[89]  Paul Young,et al.  Molecular Basis for Cross-Linking of Actin Filaments: Structure of the α-Actinin Rod , 1999, Cell.

[90]  S. Strakowski,et al.  Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. , 1999, Archives of general psychiatry.

[91]  M. Waters,et al.  of Insulin-Like Growth , 1993 .